Creator: Help Dementia Editorial Team
Published: 2026-04-02T09:39:27

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Denied claims sits at the center of this dementia and brain health question.

Denied insurance claims directly compromise treatment success for dementia patients by creating delays that allow the disease to progress unchecked. When a caregiver submits a claim for a newly prescribed dementia medication like Leqembi—a breakthrough drug that halts cognitive decline in early-stage Alzheimer’s—and the insurance company denies it because the medication isn’t on their approved list or they want the patient to try a cheaper alternative first, that delay of weeks or months means irreplaceable neurons continue to deteriorate. By the time the appeal is won, the window for effective intervention may have narrowed. This article examines how claim denials specifically undermine dementia treatment outcomes, explores why certain patients face higher denial rates, and details the gap between FDA-approved breakthrough treatments and what insurance actually covers.

The problem is systemic: Medicare Advantage plans deny 17% of initial claims, though 66% of resubmitted denials are ultimately overturned. The fact that two-thirds of denials are reversed suggests insurers routinely reject claims that should have been approved. For dementia patients, this isn’t simply a paperwork inconvenience—it’s a clinical setback. Each month of delayed treatment represents additional cognitive loss that cannot be recovered.

Why Insurance Claims Get Denied for Dementia Treatment
How Delayed Treatment Creates Cascading Health Consequences
Long-Term Care Coverage and Cognitive-Only Impairment
The Appeals Process: Understanding What Actually Works
Income Disparities in Claim Denial Rates
The Treatment Innovation Gap: New Drugs, Limited Access
The Broader Coverage Question: Why New Treatments Remain Unavailable
Conclusion

Why Insurance Claims Get Denied for Dementia Treatment

insurance denials for dementia care typically occur for four distinct reasons: the insurance company identifies lower-cost alternatives that haven’t been tried, new treatments haven’t yet received coverage approval, prescribed medications aren’t on the insurance plan’s approved drug list, or medical supplies are deemed “not medically necessary.” These denials often reflect an insurance company’s cost-containment strategy rather than evidence-based clinical judgment. Documentation quality plays a critical but underappreciated role. Poor dementia documentation—particularly before advanced stages when symptoms are still subtle—directly hinders insurance approval for condition-specific medications.

A patient with mild cognitive impairment might have test scores that border on normal, making it difficult to justify to an insurance reviewer why they need an expensive, newly approved treatment. Insurance companies often demand extensive neuropsychological testing, brain imaging results, and specialist notes before they’ll approve coverage, even when a patient’s primary care physician and neurologist both recommend the treatment. This documentation burden falls on families already overwhelmed by a new diagnosis.

Why Insurance Claims Get Denied for Dementia Treatment

How Delayed Treatment Creates Cascading Health Consequences

The real danger of claim denials lies in the timing. Dementia is a progressive neurodegenerative disease where early intervention with new treatments like Leqembi and Kisunla shows the most promise. Two recently approved amyloid-clearing medications demonstrated that 92% of patients achieved no measurable amyloid plaques after 28 weeks of treatment, with low rates of amyloid-related imaging abnormalities (ARIA), the side effect that had previously limited these drugs. However, these outcomes are most robust in early-stage disease. By the time an insurance appeal is resolved and treatment finally begins, a patient may have progressed from mild cognitive impairment to moderate dementia—a stage where the same treatment may be less effective. Coverage denials impede timely diagnosis and treatment, resulting in exacerbated symptoms and lower quality of life for individuals with dementia.

The delay doesn’t just affect cognitive outcomes; it ripples through the entire care ecosystem. A patient whose treatment is delayed may require more intensive caregiving support sooner, leading to increased caregiver burnout, earlier nursing home placement, and higher overall healthcare costs. In one real-world scenario, a 68-year-old woman diagnosed with early-stage Alzheimer’s waited four months while her insurance company appealed her neurologist’s recommendation for a newly approved treatment. During those four months, she went from being able to manage most daily activities independently to needing reminders for medications and meal preparation—functional decline that would have been prevented if treatment had started immediately. However, if documentation is thorough and the appeal is handled by the insurance company’s medical review team (rather than a purely algorithmic denial), the odds of overturning the denial improve significantly. This suggests that the problem isn’t always the treatment’s evidence base—it’s the information the insurance company receives.

Long-Term Care Coverage and Cognitive-Only Impairment

One of the most problematic coverage gaps occurs with long-term care insurance. Long-term care insurers are often skeptical of cognitive-only impairment—the hallmark of early-stage dementia, which affects cognitive function before physical abilities decline. A patient may be fully independent in walking, dressing, and eating but unable to manage finances or medications due to dementia. Many long-term care policies require evidence of deficits in activities of daily living (ADLs) like bathing and toileting to trigger benefits. Without clear documentation of how dementia specifically impairs these ADLs, insurers frequently deny long-term care claims, leaving families with no coverage for in-home care, assisted living, or memory care facilities. This creates a perverse incentive structure: patients don’t receive insurance support until their dementia has progressed to the point where they need physical assistance.

Early, aggressive treatment that might preserve cognitive function and delay or prevent physical dependency is therefore not covered, while later-stage care is expensive and extensive. A family that could have prevented intensive caregiving needs through early treatment instead finds itself paying out-of-pocket for advanced care years later. Documentation of cognitive deficits must be specific and measurable. General statements like “patient has memory problems” or “patient is confused at times” are often insufficient. Insurance companies expect neuropsychological test results, Mini-Cog or Montreal Cognitive Assessment scores, and detailed functional decline narratives. Many dementia patients don’t receive formal cognitive testing until significant decline has occurred, meaning the documentation needed to support earlier treatment claims may not exist.

Long-Term Care Coverage and Cognitive-Only Impairment

The Appeals Process: Understanding What Actually Works

The fact that 60% of denied claims are resubmitted—and 66% of those resubmitted denials are ultimately overturned—reveals that many denials are actually reversible. Understanding how to appeal effectively can make the difference between accessing breakthrough treatment and aging out of the treatment window. Successful appeals typically involve three components: obtaining detailed documentation from the treating physician about why standard treatments have failed or are contraindicated, submitting peer-reviewed research supporting the requested treatment, and including a narrative explaining the clinical reasoning for why the specific medication or service is medically necessary for this specific patient. Insurance denials are often based on incomplete information.

When a neurology specialist sends a detailed letter explaining that a patient has contraindications to cheaper alternative medications, or when research is submitted showing that early intervention with amyloid-clearing drugs prevents functional decline, insurance medical reviewers frequently reverse their initial denials. The tradeoff is time and expertise: filing an effective appeal requires resources that not all patients and families have. A sophisticated patient with a specialist physician and the ability to track appeals may successfully fight a denial and get treatment within 2-3 months. A patient without that support system may accept the denial and never receive the treatment. This creates a stark inequality: those with better documentation, better-informed physicians, and time to navigate appeals get access to life-altering treatments, while others do not.

Income Disparities in Claim Denial Rates

Income is a critical determinant of who experiences insurance claim denials. Patients in the lowest income group had 43% higher odds of experiencing any claim denial compared to those in the highest income group. This disparity isn’t primarily about the treatments themselves—it’s about documentation quality, physician expertise, and the ability to appeal.

Lower-income patients are more likely to receive care from primary care physicians in underresourced settings, clinicians who may lack specialized dementia training and may not document cognitive decline with the precision insurance companies demand. They’re also less likely to see neurologists or cognitive specialists who maintain detailed records and relationship with insurance companies’ medical review teams. When a Medicare Advantage denial arrives, a low-income patient is less likely to have the time off work to manage an appeal or the financial cushion to pay out-of-pocket while waiting for approval. This compounds over time: delayed access to early treatment means more rapid progression, earlier need for institutional care, and higher total lifetime healthcare costs—borne both by the patient and the healthcare system.

Income Disparities in Claim Denial Rates

The Treatment Innovation Gap: New Drugs, Limited Access

Despite FDA approval, the most promising new dementia treatments face significant adoption barriers. One hundred thirty-eight drugs are currently in dementia clinical trials—182 trials total—with 8 new drug readout decisions expected in 2026. However, patients in rural and remote regions, as well as those in low-income areas, face substantial barriers to accessing these emerging treatments.

Even when drugs are approved and technically covered by insurance, not all regions have infusion centers equipped to administer them, and not all neurologists have completed the required training. Leqembi and Kisunla, the two amyloid-clearing treatments that have shown remarkable efficacy in early-stage Alzheimer’s disease, are infusion-based therapies that require patient monitoring. A patient in an urban area near a specialized dementia center might receive treatment within weeks of diagnosis; a patient 100 miles from the nearest infusion center might wait months or never receive it. Insurance coverage is only half the battle; infrastructure and specialist availability are equally important determinants of treatment access.

The Broader Coverage Question: Why New Treatments Remain Unavailable

The United Kingdom’s National Health Service illustrates a systemic adoption gap. Despite FDA approvals of breakthrough dementia treatments, most new dementia therapies are not adopted by the NHS, with care centering instead on symptom management with older medications. This reflects a broader truth: insurance coverage decisions—whether driven by cost constraints, evidence review practices, or bureaucratic inertia—lag behind clinical capability.

A patient with early-stage Alzheimer’s might have a medication available that could preserve their cognitive function for years, yet never receive it because their insurance hasn’t updated its coverage policies or their healthcare system hasn’t implemented new treatment pathways. As new dementia drugs continue to emerge from the 182 trials currently underway, coverage gaps will likely persist. Insurance companies will face pressure to expand coverage; physicians will advocate for their patients; and families will increasingly need to navigate complex appeals and seek alternatives like clinical trials or out-of-pocket payment. The question is whether insurance coverage evolves quickly enough to match the pace of clinical innovation.

Conclusion

Denied insurance claims compromise dementia treatment success through three mechanisms: they delay access to time-sensitive breakthrough therapies, they create disparities that systematically disadvantage lower-income patients, and they reflect systemic gaps between what medicine can do and what insurance companies actually cover. The 17% denial rate for Medicare Advantage claims, coupled with the 43% higher denial odds for low-income patients, reveals that dementia treatment access is not equally distributed.

The path forward requires patients and caregivers to understand that many denials are reversible—66% of resubmitted denials are overturned—and that effective appeals rely on thorough documentation, specialist input, and persistence. Simultaneously, broader policy change is needed to accelerate coverage decisions for FDA-approved treatments and ensure that emerging dementia therapies don’t remain inaccessible to those in underserved regions or lower-income brackets.